LEO Pharma A/S and LTS Lohmann Therapie-Systeme AG initiate first-ever clinical trial of microarray patches for psoriasis treatment
Andernach, DE, and Ballerup, DK, March 19, 2019: LTS Lohmann Therapie-Systeme AG (LTS), a market leader in transdermal therapeutic systems, and LEO Pharma A/S, a global leader in dermatology, today announced that the companies will start the clinical trial of microarray patches for the local intradermal treatment of psoriasis. The study will start in April 2019 with expected completion later this year and the aim of the study is to document safety and efficacy in patients.
A microarray patch (also known as a microneedle patch) is a polymeric, microscopic array which delivers encapsulated drugs by perforating the outer stratum corneum with numerous microneedles. The needles are biodegradable and will dissolve as they release the drug in the skin.
This is the first time that microarray patch technology is applied to psoriasis treatment, representing a novel dosage form with several potential benefits for patients: The microarray patch enables slow release of the drug (betamethasone and calcipotriol), which means that treatment frequency can potentially be reduced from one or more times daily to once weekly. Furthermore the patch may reduce or potentially eliminate the need for application of topicals such as ointments. Application of the patch is precise due to the small size of the micro needles ensuring that only affected skin is treated.
The micro array patch for psoriasis treatment has been developed jointly between LEO Pharma and LTS’ laboratories and has Good Manufacturing Practice (GMP) status. The project is the first result of a partnership agreement which the two companies entered in 2016.
“After a successful preclinical development in the last two years, initiating a human study in corporation with LEO Pharma is the next major milestone. Our Micro Array Patch (MAP) platform allows the active ingredient to be released directly into the skin MAP innovation is driven by a productive and constructive cooperation using core competences of LEO Pharma and LTS,” said Stefan Henke, Head of LTS‘s Innovative Injection Systems Unit.
“Our alliance with LTS is a great example of LEO Pharma’s innovative approach to psoriasis treatment and how we collaborate to improve and extend what’s possible for the benefit of patients. The microarray patch represents a new treatment method, which we believe has the potential to improve both treatment compliance and convenience – thus helping even more patients achieve healthy skin,” said Kim Kjøller, Executive Vice President, LEO Pharma Research & Development.
LTS Lohmann Therapie-Systems AG: Dr. Iris Schnitzler, Marketing and Market Services,
LEO Pharma A/S: Trine Juul Wengel, Global External Communications
email@example.com, Tel.: +45 20732037
Information om LEO Pharma
About LTS Lohmann Therapie-Systeme AG LTS is a leading pharmaceutical technology company that develops and manufactures innovative drug delivery systems such as Transdermal Patches (“TTS”) and Oral Thin Films (“OTF”) for the pharmaceutical industry. LTS´ commercial offering encompasses more than 20 marketed products and a diverse pipeline of more than 30 development projects targeting multiple disease indications. LTS’s innovation pipeline contains both partner-funded as well as proprietary, LTS-funded projects. LTS maintains its leading position through the continuous refinement of its core TTS and OTF technologies and by advancing emerging drug delivery technologies, including Micro Array Patches for the transdermal delivery of large molecule, biological actives. Founded in 1984, LTS operates today from two sites in Andernach, Germany and West Caldwell, NJ, USA and a representation in Shanghai, China.
About LEO Pharma LEO Pharma helps people achieve healthy skin. The company is a leader in medical dermatology with a robust R&D pipeline, a wide range of therapies and a pioneering spirit. Founded in 1908 and owned by the LEO Foundation, LEO Pharma has devoted decades of research and development to advance the science of dermatology, setting new standards of care for people with skin conditions. LEO Pharma is headquartered in Denmark with a global team of 5,700 people, serving 80 million patients in 130 countries. In 2017, the company generated net sales of euro 1.4 billion.
Følg pressemeddelelser fra LEO Pharma
Skriv dig op her, og modtag pressemeddelelser på e-mail. Indtast din e-mail, klik på abonner, og følg instruktionerne i den udsendte e-mail.
Flere pressemeddelelser fra LEO Pharma
LEO Pharma and Research Project BIOMAP: Towards Personalised Medicine for Inflammatory Skin Diseases11.4.2019 11:40:51 CEST | Pressemeddelelse
The large-scale IMI project will investigate the causes and mechanisms of Atopic Dermatitis and Psoriasis
LEO Pharma and Elektrofi expand partnership to co-develop new antibodies with the aim of achieving improvements in drug delivery within dermatology9.4.2019 10:00:56 CEST | Pressemeddelelse
Ballerup, April 9, 2019: LEO Pharma A/S, a global leader in medical dermatology and Elektrofi, a Boston- based biotechnology company focused on drug formulation and delivery innovations, today announced an expansion of the two companies’ partnership agreement (signed in 2017) to further include antibodies from LEO Pharma’s pipeline with the aim of achieving improvements in drug delivery within dermatology.
Olivier Bohuon elected new chairman of LEO Pharma’s Board of Directors28.2.2019 00:10:03 CET | Pressemeddelelse
BALLERUP, Denmark, 28 February 2019 – LEO Pharma today announced changes to its Board of Directors. Olivier Bohuon is announced new chairman of the Board of Directors succeeding Jukka Pertola, who has decided to leave the Board. Member of the Board Anders Ekblom will assume a new position as vice chairman. In addition, John Weeks decided to not seek re-election.
LEO Pharma Annual Results 2018: A year in line with expectations28.2.2019 00:08:59 CET | Pressemeddelelse
- 2018 revenue of DKK 10,410 million - Strong progress on 2025 Strategy - Strengthened innovative clinical pipeline - Expanded established portfolio
Forskere fra LEO Pharma hyldes med Innovationsfondens Innovatørpris 20191.2.2019 15:01:40 CET | Pressemeddelelse
Excellent og banebrydende forskning, som skaber værdi for Danmark, er i fokus, når Innovationsfonden i dag uddeler årets priser. Det er derfor med stor stolthed, at LEO Pharma i dag kan meddele, at to af virksomhedens forskere, Marianne Lind, Ph.d. Senior Scientist og Karsten Petersson, Ph.d. Director, er udvalgt til at modtage Innovatørprisen 2019. Det er tredje år i træk, at prisen uddeles, og tildelingen af årets Innovatørpris til Marianne Lind og Karsten Petersson, som begge arbejder inden Explorative Formulation & Technologies hos LEO Pharma, sker på baggrund af følgende vurderinger: Den værdiskabelse, kandidaterne har skabt for såvel virksomhed som patienter Kandidaternes evne til at omsætte excellent forskningsviden til konkrete løsninger De to forskere modtager prisen for udviklingen af Enstilar®, LEO Pharmas skumspray til behandling af psoriasis. Enstilar® blev godkendt af Lægemiddelstyrelsen og kom på markedet i Danmark i 2016. Produktet anvendes i dag af flere end en million
LEO Pharma further Boosts Focus on Translational Medicine with the Appointment of Thomas Hultsch, M.D., Ph.D., as Head of Translational Medicine28.1.2019 10:15:51 CET | Pressemeddelelse
Ballerup, Denmark, 28 January, 2019 – LEO Pharma, a global leader in medical dermatology, today announced that Thomas Hultsch, M.D., Ph.D., has been appointed as Head of Translational Medicine as of 28 January, 2019.
I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter samt finde vores kontaktoplysninger.Besøg vores nyhedsrum